Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9)

Orly Vardeny; James C. Fang; Akshay S. Desai; Pardeep S. Jhund; Brian Claggett; Muthiah Vaduganathan; Rudolf A. de Boer; Adrian F. Hernandez; Carolyn S.P. Lam; Silvio E. Inzucchi; Felipe A. Martinez; Mikhail N. Kosiborod; David DeMets; Eileen O’Meara; Shelley Zieroth; Josep Comin-Colet; Jaroslaw Drozdz; Chern En Chiang; Masafumi Kitakaze; Magnus Petersson; Daniel Lindholm; Anna Maria Langkilde; John J.V. McMurray; Scott D. Solomon

doi:10.1038/s41591-023-02302-x

Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9)

Orly Vardeny^*, James C. Fang, Akshay S. Desai, Pardeep S. Jhund, Brian Claggett, Muthiah Vaduganathan, Rudolf A. de Boer, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Mikhail N. Kosiborod, David DeMets, Eileen O’Meara, Shelley Zieroth, Josep Comin-Colet, Jaroslaw Drozdz, Chern En Chiang, Masafumi Kitakaze, Magnus PeterssonDaniel Lindholm, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

Correction to: Nature Medicine. Published online 15 December 2022. In the version of this article initially published, there was an error in the abstract, where in the sentence now reading, in part, “In participants with HFimpEF… first worsening heart failure events (HR = 0.84),” the hazard ratio originally read “0.78,” while in the second paragraph of the “Outcomes by HFimpEF status” Results subsection, in the sentence now reading, in part, “The effect of dapagliflozin on HF outcomes was also similar in those with HFimpEF (HR = 0.84, 95% CI = 0.61–1.14) and those with LVEF consistently over 40% (HR = 0.78),” the hazard ratio values were mistakenly interchanged. The values have been updated in the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	3269
Number of pages	1
Journal	Nature Medicine
Volume	29
Issue number	12
DOIs	https://doi.org/10.1038/s41591-023-02302-x
Publication status	Published - Dec 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).

Access to Document

10.1038/s41591-023-02302-x

Cite this

Vardeny, O., Fang, J. C., Desai, A. S., Jhund, P. S., Claggett, B., Vaduganathan, M., de Boer, R. A., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., Martinez, F. A., Kosiborod, M. N., DeMets, D., O’Meara, E., Zieroth, S., Comin-Colet, J., Drozdz, J., Chiang, C. E., Kitakaze, M., ... Solomon, S. D. (2023). Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9). Nature Medicine, 29(12), 3269. https://doi.org/10.1038/s41591-023-02302-x

@article{2a2be08f1d944583992aeb44ab28d6f2,

title = "Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9)",

abstract = "Correction to: Nature Medicine. Published online 15 December 2022. In the version of this article initially published, there was an error in the abstract, where in the sentence now reading, in part, “In participants with HFimpEF… first worsening heart failure events (HR = 0.84),” the hazard ratio originally read “0.78,” while in the second paragraph of the “Outcomes by HFimpEF status” Results subsection, in the sentence now reading, in part, “The effect of dapagliflozin on HF outcomes was also similar in those with HFimpEF (HR = 0.84, 95% CI = 0.61–1.14) and those with LVEF consistently over 40% (HR = 0.78),” the hazard ratio values were mistakenly interchanged. The values have been updated in the HTML and PDF versions of the article.",

author = "Orly Vardeny and Fang, {James C.} and Desai, {Akshay S.} and Jhund, {Pardeep S.} and Brian Claggett and Muthiah Vaduganathan and {de Boer}, {Rudolf A.} and Hernandez, {Adrian F.} and Lam, {Carolyn S.P.} and Inzucchi, {Silvio E.} and Martinez, {Felipe A.} and Kosiborod, {Mikhail N.} and David DeMets and Eileen O{\textquoteright}Meara and Shelley Zieroth and Josep Comin-Colet and Jaroslaw Drozdz and Chiang, {Chern En} and Masafumi Kitakaze and Magnus Petersson and Daniel Lindholm and Langkilde, {Anna Maria} and McMurray, {John J.V.} and Solomon, {Scott D.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1038/s41591-023-02302-x",

language = "English",

volume = "29",

pages = "3269",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "12",

}

Vardeny, O, Fang, JC, Desai, AS, Jhund, PS, Claggett, B, Vaduganathan, M, de Boer, RA, Hernandez, AF, Lam, CSP, Inzucchi, SE, Martinez, FA, Kosiborod, MN, DeMets, D, O’Meara, E, Zieroth, S, Comin-Colet, J, Drozdz, J, Chiang, CE, Kitakaze, M, Petersson, M, Lindholm, D, Langkilde, AM, McMurray, JJV & Solomon, SD 2023, 'Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9)', Nature Medicine, vol. 29, no. 12, pp. 3269. https://doi.org/10.1038/s41591-023-02302-x

Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9). / Vardeny, Orly; Fang, James C.; Desai, Akshay S. et al.
In: Nature Medicine, Vol. 29, No. 12, 12.2023, p. 3269.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Author Correction

T2 - Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9)

AU - Vardeny, Orly

AU - Fang, James C.

AU - Desai, Akshay S.

AU - Jhund, Pardeep S.

AU - Claggett, Brian

AU - Vaduganathan, Muthiah

AU - de Boer, Rudolf A.

AU - Hernandez, Adrian F.

AU - Lam, Carolyn S.P.

AU - Inzucchi, Silvio E.

AU - Martinez, Felipe A.

AU - Kosiborod, Mikhail N.

AU - DeMets, David

AU - O’Meara, Eileen

AU - Zieroth, Shelley

AU - Comin-Colet, Josep

AU - Drozdz, Jaroslaw

AU - Chiang, Chern En

AU - Kitakaze, Masafumi

AU - Petersson, Magnus

AU - Lindholm, Daniel

AU - Langkilde, Anna Maria

AU - McMurray, John J.V.

AU - Solomon, Scott D.

PY - 2023/12

Y1 - 2023/12

N2 - Correction to: Nature Medicine. Published online 15 December 2022. In the version of this article initially published, there was an error in the abstract, where in the sentence now reading, in part, “In participants with HFimpEF… first worsening heart failure events (HR = 0.84),” the hazard ratio originally read “0.78,” while in the second paragraph of the “Outcomes by HFimpEF status” Results subsection, in the sentence now reading, in part, “The effect of dapagliflozin on HF outcomes was also similar in those with HFimpEF (HR = 0.84, 95% CI = 0.61–1.14) and those with LVEF consistently over 40% (HR = 0.78),” the hazard ratio values were mistakenly interchanged. The values have been updated in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicine. Published online 15 December 2022. In the version of this article initially published, there was an error in the abstract, where in the sentence now reading, in part, “In participants with HFimpEF… first worsening heart failure events (HR = 0.84),” the hazard ratio originally read “0.78,” while in the second paragraph of the “Outcomes by HFimpEF status” Results subsection, in the sentence now reading, in part, “The effect of dapagliflozin on HF outcomes was also similar in those with HFimpEF (HR = 0.84, 95% CI = 0.61–1.14) and those with LVEF consistently over 40% (HR = 0.78),” the hazard ratio values were mistakenly interchanged. The values have been updated in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85150020835&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02302-x

DO - 10.1038/s41591-023-02302-x

M3 - Comment/Letter to the editor

C2 - 36932245

AN - SCOPUS:85150020835

SN - 1078-8956

VL - 29

SP - 3269

JO - Nature Medicine

JF - Nature Medicine

IS - 12

ER -

Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (Nature Medicine, (2022), 28, 12, (2504-2511), 10.1038/s41591-022-02102-9)

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this